Itismeran autogene + Keytruda demonstrated improvement in recurrence-free survival in neoadjuvant melanoma

CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study

In the phase II CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate CAR T-cell therapy in patients with high-risk smoldering multiple myeloma, all 20 patients were negative for minimal residual disease within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up.

April 24, 2026

Vol.52 No.16

Cancer Policy

FDA issues reminder to sponsors: Disclose clinical trial results

FDA issued a stern reminder to medical product companies and researchers of the requirements to submit certain clinical trial results information to ClinicalTrials.gov.

Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

The START Center for Cancer Research, a community-based network of clinical trial sites specializing in early-phase oncology trials, announced the appointment of Salwan Al Mutar as director of Clinical Research at START Dallas-Fort Worth.

April 17, 2026

Vol.52 No.15

In Brief

Destination Healthy Skin RV will provide free skin exams in 40 U.S. cities

The Skin Cancer Foundation is bringing Destination Healthy Skin to 40 cities in 22 states this year. The Foundation kicked off its 2026 mobile education and screening program on April 15 in Columbus, Ohio.

April 17, 2026

Vol.52 No.15

Clinical Roundup

ATOMIC phase III trial establishes standard-of-care for patients with stage 3 dMMR colon cancer

Patients with stage 3 colon cancer with deficient DNA mismatch repair had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq) was added to standard chemotherapy after surgery, according to a study by researchers at the Alliance for Clinical Trials in Oncology.

April 17, 2026

Vol.52 No.15

Clinical Roundup

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

Patients with pancreatic cancer who received the experimental drug elraglusib, alongside standard chemotherapy, were twice as likely to be alive after one year of treatment, compared to those receiving chemotherapy alone, according to the results of a randomized phase II clinical trial conducted by researchers at Northwestern University. The drug also reduced the risk of death by 38%.

April 17, 2026

Vol.52 No.15

Itismeran autogene + Keytruda demonstrated improvement in recurrence-free survival in neoadjuvant melanoma

YOU MAY BE INTERESTED IN

CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study

FDA issues reminder to sponsors: Disclose clinical trial results

Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

Destination Healthy Skin RV will provide free skin exams in 40 U.S. cities

ATOMIC phase III trial establishes standard-of-care for patients with stage 3 dMMR colon cancer

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

Renew today!

Subscriber content

Never miss an issue!

Login

Itismeran autogene + Keytruda demonstrated improvement in recurrence-free survival in neoadjuvant melanoma

YOU MAY BE INTERESTED IN

CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study

FDA issues reminder to sponsors: Disclose clinical trial results

Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

Destination Healthy Skin RV will provide free skin exams in 40 U.S. cities

ATOMIC phase III trial establishes standard-of-care for patients with stage 3 dMMR colon cancer

Experimental drug doubles one-year survival in pancreatic cancer trial, Northwestern study finds

Never miss an issue!

Login

Destination Healthy Skin RV will provide free skin exams in 40 U.S. cities